Good Evening Traders,
We have been riding a massive win streak here. People say that the summer is notoriously slow but that just hasn’t been the case for us. There is always money to be made in the markets no matter what time of year it is.
A lot of research goes into the companies that we profile. We strenuously perform due diligence on every company that we profile and hand pick only a few that I feel are really worthy of your attention.
This next company caught my attention because of the industry that they are in and because of the recent activity in the stock.
They are in a $5.5 Billion marketplace and are about to jump head first into one of the most populous and growing economies in the world in early 2012.
Let’s put EAPH on our radar for Thursday’s trading session.
EAPH TECHNICALS
Volume has increased significantly over the last 3 weeks as EAPH undergoes it’s basing process.
EAPH has strong support in the .10 to .12 range.
Any type of a positive volume surge can potentially lead to a re-test of recent highs at .20 cents where a mini double top was formed.
A break of this double top would be extremely bullish and could ignite a test of the .24 cent level.
Very minor layers of resistance also remain at the .17 and .18 cent levels.
EAPH’s PRODUCTS
Ever since Pfizers “Blue Miracle Pill” for men exploded on to the scene with blockbuster success, the industry has sought to produce a similar result for women.
EAPH met the challenge head on and has developed a product called Viorra.
Viorra is EAPH’s first product to market. Viorra is a female “enhancement” gel. Female Sexual Dys-function (FSD) is estimated to affect 43% of women, with many women experiencing hypoactive sexual des ire disorder (HSDD) or low appetite at some point in their lives. Viorra has been specifically formulated to enhance the female experience with safe and effective vaginal revitalization and increased stimulation.
Viorra is an all-natural, hormone free, non-toxic, topical gel that is endorsed by some of the world’s leading medical experts on women’s sexuality. The doctor recommended daily use of Viorra Sensuality Solution helps to restore and improve moisture and vaginal elasticity, improving functioning for women. The improvement of ual functioning of women has a positive effect on sexual appetite, arousal and the ability to experience orgasms. Viorra is also designed to be used during sexual intimacy to enhance sexual activity by improving lubrication and providing a warm and pleasurable stimulating sensation. This unique product will be marketed as a premium cosmetic product developed specifically for women interested in maintaining and improving their sexual health and intimate relationships.
Viorra has completed and passed irritation, allergic reaction, oral toxicity and three year stability studies. Viorra has completed an Open Label Clinical Pilot Trial to evaluate the safety and efficacy of the product. Pre and post-menopausal women with pre-diagnosed SDD for the past five years tested Viorra. There were no adverse data reported during the study and collectively the subjects reported: Less genital pain during intercourse, more sexual attempts with their partner, increase in vaginal lubrication, higher incidence of orgasm, increased desire to engage in sexual activity and an overall increase in sexual satisfaction.
SOUNDS LIKE A PRETTY GOOD PRODUCT!!
RECENT EAPH NEWS
(7-22-11) Easton Pharmaceuticals Announces Projections of $15 Million in Revenue For 2012 From The Company’s First Territory Launch of VIORRA in Mexico
http://finance.yahoo.com/news/Easton-Pharmaceuticals-iw.html?x=0&.v=1
BMV estimates the regulatory approval process will be completed in early
2012. In parallel with the regulatory filing, Easton Pharmaceuticals
under the guidance of BMV has begun talks with several large
distribution companies that are focused on sales and marketing in the
women’s health market. Easton Pharmaceuticals” believes that with both
the regulatory and commercial alliance initiatives running in parallel
will enable a timely, successful launch of VIORRA and generate upwards
of $15 million annual company revenue from Mexico beginning in 2012.
MORE ABOUT EAPH
Easton Pharmaceuticals is a specialty pharmaceutical company that designs, develops and markets a range of premium, topically delivered therapeutic health care products. The company’s proprietary gel formulation is an innovative and unique transdermal delivery system.
The system is the technology that allows for the rapid development of non-invasive, naturally derived topical solutions that have the ability to revitalize and stimulate the healing of a variety of skin and tissue conditions. The transdermal delivery system allows for the targeted delivery of active ingredients, vitamins and herbs through the skin to the underlying tissue.
The company has utilized its transdermal delivery system to develop a safe and effective female sexual enhancement product. The company’s goal is to develop a portfolio of topical pharmaceutical and cosmeceutical products targeting various skin and tissue conditions including: scars and stretch marks, cellulite and varicose veins.
_____________________________________
EAPH is on high alert for Thursday.
I have more to come on EAPH before the open. Start your research here: www.eastonpharma.com & http://finance.yahoo.com/q?s=EAPH.PK&ql=0
Remember to always consult a professional before investing to determine suitability and always do your own research on any company mentioned.
Always protect your investment and profits with stop loss orders and/or trailing stops if possible.
Past performance in never indicative of future results.
Sincerely,
PSE
17(B) DISCLAIMER www.PennyStockExplosion.com, its owners, and their affiliates, directors and officers, and immediate family members, are hereafter collectively referred to as “PSE” or “we” or “us” or “our). PSE electronically disseminates information (the “Information”) on its website, in newsletters, featured reports, spam compliant opt in email communications or otherwise pertaining to Profiled Companies’ (the “Issuer” or “Issuers” or “Profiled Company” or “Profiled Companies”), the securities of which are most frequently common stock shares quoted on the Over the Counter Bulletin Board (“OTCBB”) or Pink Sheets. The Information is based on information received from Issuers, publicly available information, such as quarterly (with unaudited financial statements) and annual reports (with audited financial statements) filed with the Securities and Exchange Commission (“SEC”), quarterly and annual unaudited financial reports and Information and Disclosure Statements filed with the Pink Sheets, the Issuer’s website and information obtained through search engines such as Yahoo Finance, Market Watch and Business Wire. We synthesize the Information from these informational sources for our Readers as a starting point for further inquiry into the Issuer and its securities. Because PSE receives compensation for PSE’s dissemination of the Information (as disclosed in our Compensation Disclosure Section), PSE should not be considered to be an independent provider of the Information. PSE is not a research analyst, registered investment advisor or registered securities broker dealer and the Information should not be construed in any manner, shape or form as investment-advice, investment recommendations or opinions or viewpoints regarding the Profiled Company or its securities or as a solicitation to offer, purchase or sell the Profiled Company’s securities. PSE does not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information and conducts no due diligence whatsoever of the Profiled Companies. Because the Information is presented on an “as is” basis, your use of the Information is at your own risk. PSE disclaims, expressly and impliedly, all warranties of any kind, including whether the Information is accurate or reliable or free of errors. By reading the Information, the Reader hereby agrees to indemny and hold PSE harmless from any liability for any claimed direct, indirect, incidental, punitive, or consequential damages pertaining to the Information. Statements contained in the Information that are not historical facts are fwd looking statements that involve risks and uncertainties as indicated by words such as “believes”, “expects”, “estimates”, “may”, “will” or “should” or “anticipates” or similar expressions. These fwd looking statements may materially differ from the Issuer’s actual operational and financial results or its actual achievements, claimed or otherwise. PSE does not undertake any responsibility whatsoever of these fwd looking statements, nor any legal obligation whatsoever of updating the Information. The Information is presented only as a brief “snapshot” of the Profiled Company and should only be used, at most, and if at all, as a starting point for Readers to conduct a thorough investigation of the Profiled Company and its securities, to consult with their financial, legal or other advisor(s) and avail themselves of filings and information that may be accessed at www.sec.gov . or www.pincksheets.com or other electronic medium, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets; (c) obtaining and reviewing publicly available information contained in commonly known search engines such as Google; and (e) consulting investment guides at www.sec.gov and www.finra.com pertaining to the risks of investing in micro caps. In the end result, Readers must evaluate and bear all the risks associated with the Information, including reliance on its accuracy, completeness or usefulness. In all instances, the Reader should conduct further inquiry into the Profiled Company and its securities. The Profiled Companies are subject to possible risks, including but not limited to: (a) the Information pertains to micro caps that are subject to the SEC’s penny_stock rules and commonly involve a high degree of risk that may result in the loss of some or all of an investment in the Profiled Company’s securities; (b) the Issuer’s penny_ stock may be thinly traded, which may lead to difficulties of selling its securities; (c) the SEC reporting issuer may be delinquent (not current) in its periodic reporting obligations (i.e., in its quarterly and annual reports) or the Pink Sheet quoted company may be delinquent in its Pink Sheet reporting obligations as indicated by Pink Sheets New Service’s posting a negative “sign” pertaining to the Issuer at www.pinksheets.com , as follows: (i) “Limited Information” for companies with financial reporting problems, economic distress, or that are unwilling to file required reports with the Pink Sheets; (ii) “Pink Sheets – No Information”, which indicates companies that are unable or unwilling to provide disclosure to the public markets, to the SEC or the Pink Sheets; and (iii) “Caveat Emptor”, signifying “Buyer Beware” that there is a public interest concern associated with a company’s illegal spam campaign, questionable stock promotion, known investigation of a company’s fraudulent activity or its insiders, regulatory suspensions or disruptive corporate actions; (d) whether the Issuer is a development stage company with little or no operations, the securities of which should be considered extremely speculative for investment purposes; (e) PSE’s selling of an Issuer’s securities may cause its stock price to significantly decline, especially when such securities are thinly traded; (f) many companies that have their securities quoted on the OTCBB or Pink Sheets (as well as even Exchange listed companies) have been negatively affected by the current economic downturn and lack of adequate financing to meet their operational goals or expansion plans; (g) any percentage gain from the previous day close presented on our website at is not and should not be construed as any indication whatsoever of the future stock price of an Issuer’s securities or its operational results; (h) many of the energy related and other Profiled Companies are subject to increasing environmental and other governmental regulations, which subjects them to significant costs and possible fines and liabilities for failure to comply with applicable state and federal statutes; (i) PSE may receive compensation in shares of the Issuer and it or its associates, affiliated entities, officers, directors or immediate family members may sell the Shares immediately upon their receipt as well as during the dissemination of such Information or within hours, days, weeks or months thereafter, or at any time; as a result, PSE’s selling activities may cause significant volatility in the Issuer’s stock price and/or significantly depress the Issuer’s stock price; (j) PSE may buy and sell the Shares in the open market before, during or after the dissemination of the Information or at any time, which may cause significant volatility including drops in the price of the Issuer’s stock price and/or significantly depress the Issuer’s stock price; (k) future success of many OTCBB and Pink Sheet quoted Issuers is dependent upon receiving adequate financing or raising sufficient capital, which they may be unable to obtain; (l) there is an inherent and actual conflict of interest that exists between our Readers’ interests and PSE’s interests because PSE’s owners, PSE: (i) receive the Shares as compensation for disseminating the Information and thereafter sell those Shares at any time for monetary gain, including at the same time the Information is being disseminated or shortly thereafter or at any time; and (ii) buys and sells the Profiled Company’s shares in the open market at the same time or before the Information is being disseminated or shortly after the dissemination of the Information or at any time; (m) we do not receive any direct verification from the Issuer regarding the Information; (n) a third party shareholder may have a potential or actual conflict of interest in paying PSE for the dissemination of the publication while still holding the Issuer’s shares of common stock that he or she may sell after the third party shareholder has paid PSE with his or her shares; (o) the Information should not be interpreted in any shape, form or manner whatsoever as an indication of the Issuer’s future stock price or future financial performance since, among other reasons, such “comparison” companies are listed on Exchanges (i.e., the New York Stock Exchange) and trade at stock prices that are thousands of percent higher than the companies we profile; and (p) Readers may encounter difficulties determining what information contained in our publications is material or non-material making it all the more imperative that they conduct further investigation of the Profiled Company and its securities ; and (q) PSE hires third party Service Providers to electronically disseminate live news regarding the Issuer, information which we do not independently provide to the Service Provider or verify and upon which we have no control over. We pay cash consideration to the Service Providers; no securities compensation is paid to the Service Providers; and (r) our employees post messages on their individual message boards as a method of disseminating the Information on behalf of our Issuer clients which should never be used as a means of conducting analysis into the Issuers should only be used as a starting point to obtain the names of pink sheet or OTC Bulletin Board companies. The owners of PSE have been compensated 15,000 dollars by a third party, Numark Capital Corp. for a one day profile on EAPH. To view disclaimer and full compensation disclossure, please go here https://pennystockexplosion.com/disclaimer.html
Penny and Small Cap Stock Alerts